Biography
Dr. Hegde oversees clinical product development, cancer genomics, andearly-stage research, as well as regulatory and quality assurance, toaccelerate advancement of the Companys leading comprehensive genomicprofiling portfolio. She is passionate about innovation in cancer researchand translating innovations to precision medicine tools to advance care for patients. Dr. Hegde has spent nearly two decades in the biopharmaceuticalindustry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancerimmunotherapy. Prior to joining Foundation Medicine, Dr. Hegde spent 12years at Genentech. Dr. Hegde served as senior director and principalscientist in oncology biomarker development at Genentech, during which sheestablished and led the biomarker group accountable for translationalscience strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union, as well as its forthcoming diagnostic filings.

Biography
Dr. Hegde oversees clinical product development, cancer genomics, andearly-stage research, as well as regulatory and quality assurance, toaccelerate advancement of the Companys leading comprehensive genomicprofiling portfolio. She is passionate about innovation in cancer researchand translating innovations to precision medicine tools to advance care for patients. Dr. Hegde has spent nearly two decades in the biopharmaceuticalindustry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancerimmunotherapy. Prior to joining Foundation Medicine, Dr. Hegde spent 12years at Genentech. Dr. Hegde served as senior director and principalscientist in oncology biomarker development at Genentech, during which sheestablished and led the biomarker group accountable for translationalscience strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union, as well as its forthcoming diagnostic filings.

Biography
Dr. George Coukos pioneering work presently focuses on developing precision immunotherapy in cancer treatment, particularly in Tcell therapies. Notably, he's been instrumental in developing personalized immunotherapies, including an autologous dendritic cell vaccine and adoptive Tcell therapy with vaccine primed autologous Tcells for ovarian cancer treatment. Dr. Coukos's research has unveiled the spontaneous antitumor response in ovarian cancer, expanding its application beyond ovarian to other solid tumors. He also elucidated critical mechanisms governing the interplay between tumors and the immune system, including the role of the tumor vasculature in erecting a barrier to T cell trafficking in tumors. Dr. Coukos is leveraging advanced technologies like high throughput sequencing to tailor immunotherapies based on molecular and genetic specifics of the tumor cells and the tumor microenvironment. His research pursuits of innovative therapies have set new standards in cancer immunotherapy, including the recent development of rational engineering of superior effector T cell states for adoptive therapy.

Biography
Dr. Carl June studies mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronicinfection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocyticleukemia were treated with genetically engineered versions of their own T cells, CAR-Ts. The treatment has also now been used with promising results to treat children with refractory acute lymphoblastic leukemia. His work led to the development and commercialization of tisagenlecleucel, the first FDA-approved gene therapy. In the 1980s, his lab discovering the CD28 molecule as the major control switch for T cells. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors. In 2024, he won the Breakthrough Prize in Life Sciences, known as the “Oscars of Science,” for pioneering CAR T-cell immunotherapy that engineers a patient’s T cells to attack and kill cancer.

Biography
Dr. Betof Warner is a board certified medical oncologist specializing inadvanced melanoma treatment. She serves as the Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co Director of the Pigmented Lesion and Melanoma Program. A pioneer in tumor infiltratinglymphocyte (TIL) therapy, she leads the Melanoma Cutaneous Oncology Clinical Research Group, focusing on tumor response to immunotherapy. Recognized for her expertise in central nervous system metastases and novelcellular therapies, she's collaborated globally and received accolades from A SCO, NIH, and the Melanoma Research Foundation. Dr. Betof Warner is anactive member of several professional organizations, including the American Association for Cancer Research and the Society for Immunotherapy of Cancer.

Biography
Dr. Yee is an oncologist, immunologistand endowed professor in Division of Cancer Medicine, Dept of Immunology, and Director of Solid Tumor Cell Therapy at MD Anderson Cancer Center, elected to A SCI in 2009. Over the last 25 years, Dr. Yees discoveries in cell therapy provided first proof-of-concept of the importance of T cell persistence, antigen-spreading and combination strategies by pioneering the use of antigen-specific T cells in a modality known as Endogenous T Cell therapy. He holds more than 18 inventions in the field of cellular therapy and is founder of an AI startup and TCR-T cell therapy company (Mongoose Bio). Assets developed in Yee Lab are focused on solid tumors for common and rare cancers in the global population, leveraging one of the largest immunopeptidomes established from MS-defined datasets in his lab. His latest project is a NASA-funded initiative to take T cells to the International Space Station

Biography
Dr. Goff is a surgical oncologist with extensive experience in the development of cellular immunotherapy for cancer. She serves as the Head of Clinical Operations for Surgery Branch cGMP Facilities supporting multiple TIL, TCR, and CAR protocols and has received NIH and NCI Directors Awards for clinical and scientific excellence, as well as the NIH Clinical Center Clinician of the Year. Her research publications have focused on TIL for the treatment of metastatic melanoma, breast cancer, and gastrointestinal tumors.

Biography
Sadelain is a globally recognized pioneer of chimeric antigen receptor T cell (CAR-T) immunotherapy, a groundbreaking approach to cancer treatment. CAR-T therapy uses genetic engineering on a sample of a patients own T cells to transform them into living drugs for the treatment of their disease. Sadelain led the development of CAR-T cells targeting CD19 unique markers found on the surface of blood cancer cellsand established genetic engineering and cell manufacturing capabilities to translate this research. This critical groundwork enabled Sadelain and his team to start treating patients with refractory leukemias in 2007. In 2017, the FDA approved the first CAR-T therapiesthe first genetically engineered cell therapy of any kindfor childhood acute lymphoblastic leukemia and certain lymphomas. This ushered in a new class of drugs based on T cell engineering. Since then, CAR-T therapies have been approved for additional types of lymphoma and to multiple myeloma. Sadelain and his team are continuing to explore ways to make CAR-T therapies safer, more effective, and broaden their use to different types of cancers. Sadelains lab will also investigate how CAR-T engineering could be used to treat a diverse array of diseases and conditions beyond cancer, as well as sustainable means to make cell therapies more accessible. Sadelain joined Columbia University from Memorial Sloan Kettering, where he was the Stephen and Barbara Friedman Chair and director of the Center for Cell Engineering. Sadelain completed his MD at University of Paris; conducted his PhD research at the University of Alberta; and worked as a postdoctoral fellow at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology. Sadelain has been elected to the American Society for Clinical Investigation, American Association for Cancer Research, American Society for Clinical Investigation, American Society of Gene and Cell Therapy, American Academy of Arts and Sciences, and the National Academy of Medicine of France. Sadelain has won the Breakthrough Prize for Life Sciences, Canada Gairdner International Award, Warren Alpert Foundation Prize, American Society of Gene and Cell Therapy Outstanding Achievement Award, Leopold Griffuel Award, INSERM International Prize, Jacob and Louise Gabbay Award in Biotechnology and Medicine, Passano Laureate, Pasteur Weizmann Servier Prize at the Academy of Sciences in Paris, Cancer Research Institute Coley award, and more.

Biography
Sadelain is a globally recognized pioneer of chimeric antigen receptor therapy, a groundbreaking approach to cancer treatment. CAR T cells are genetically engineered cells programmed to serve as living drugs. Sadelain led the development of CAR T cells targeting CD19, a molecule found on in B cell malignancies and normal B cells, and established cell manufacturing capabilities for clinical translation. This critical groundwork enabled Sadelain and his team to treat patients with refractory leukemias in 2007. By 2017, the FDA approved the first CAR therapies, specifically for childhood acute lymphoblastic leukemia and certain lymphomas. Sadelain and his team continue to advance CAR therapies to make them safer, more effective, and more broadly applicable. Sadelain has received multiple awards for his research on human cell engineering, including most recently the Breakthrough Prize for Life Sciences, the Canada Gairdner International Award, the King Faisal prize, the Merkin prize and the Broermann Award.

Talk
New CAR Models 2026
The genetic engineering of T cells offers a means to repurpose immune cells to remedy the limitations of natural immune responses. Its first successful embodiment is chimeric antigen receptor (CAR) therapy targeting CD19. CAR T cells have not yet succeeded against solid tumors, underscoring the need for new CAR models.

Biography
Dr. Harshman leads the Clinical Development efforts at Clasp Therapeutics. A medical oncologist, she brings over 15 years of experience as a practicing physician and clinical trialist first at the patient bedside and now in biotech leadership. Most recently, Lauren served as Vice President of Clinical Development at Surface Oncology, before its acquisition by Coherus Biosciences. Earlier in her career, Dr. Harshman was on faculty at Harvard Medical School and Dana-Farber Cancer Institute, where she served as Co-Director of the Kidney Cancer Center and as a Senior Physician in the Division of Oncology. She is a graduate of Cornell University and Chicago Medical School, completed her internal medicine residency at Yale, and her medical oncology fellowship at Stanford, where she later joined the faculty at Stanford Cancer Institute and Stanford School of Medicine.

Biography
Dr. Maximilian Julvé is a clinical researcher specializing in solid tumor cellular therapies, with a focus on melanoma. His work has contributed to advancements in adoptive cell therapies, including tumor-infiltrating lymphocyte (TIL) treatments, and he has been involved in developing novel biomarkers to predict patient responses to immunotherapy. Dr Julvé's research includes the creation of a granulocyte-based scoring system aimed at enhancing prognostic assessments for patients undergoing combination immunotherapy. His publications address various aspects of immuno-oncology, such as the management of immune-related toxicities and the development of innovative therapeutic strategies for melanoma.

Biography
Alexis C. Komor is a pioneering genome‑editing researcher who co‑developed the first CRISPR base editors with David Liu at the Broad Institute. Her work established base editing as a new class of genome engineering tools that enable precise single‑nucleotide changes in DNA without double‑strand breaks, laying the foundation for correcting disease‑causing point mutations with high precision. She continues to lead efforts to translate these innovations into direct in vivo therapeutics, including strategies to deliver base editors via mRNA and other nucleic‑acid platforms to repair genes within patients’ cells. As her work established the scientific foundation of Beam Therapeutics, Komor has helped drive the clinical development of base editing, underscoring the broad impact of her work on programmable gene editing and precision medicine. Her groundbreaking contributions are influencing a new generation of in vivo RNA and gene‑based therapies (spanning mRNA, siRNA, and antisense oligonucleotide modalities) and inspiring novel small‑molecule approaches to treat genetic diseases.

Biography
Sadelain is a globally recognized pioneer of chimeric antigen receptor T cell (CAR-T) immunotherapy, a groundbreaking approach to cancer treatment. CAR-T therapy uses genetic engineering on a sample of a patients own T cells to transform them into living drugs for the treatment of their disease. Sadelain led the development of CAR-T cells targeting CD19 unique markers found on the surface of blood cancer cellsand established genetic engineering and cell manufacturing capabilities to translate this research. This critical groundwork enabled Sadelain and his team to start treating patients with refractory leukemias in 2007. In 2017, the FDA approved the first CAR-T therapiesthe first genetically engineered cell therapy of any kindfor childhood acute lymphoblastic leukemia and certain lymphomas. This ushered in a new class of drugs based on T cell engineering. Since then, CAR-T therapies have been approved for additional types of lymphoma and to multiple myeloma. Sadelain and his team are continuing to explore ways to make CAR-T therapies safer, more effective, and broaden their use to different types of cancers. Sadelains lab will also investigate how CAR-T engineering could be used to treat a diverse array of diseases and conditions beyond cancer, as well as sustainable means to make cell therapies more accessible. Sadelain joined Columbia University from Memorial Sloan Kettering, where he was the Stephen and Barbara Friedman Chair and director of the Center for Cell Engineering. Sadelain completed his MD at University of Paris; conducted his PhD research at the University of Alberta; and worked as a postdoctoral fellow at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology. Sadelain has been elected to the American Society for Clinical Investigation, American Association for Cancer Research, American Society for Clinical Investigation, American Society of Gene and Cell Therapy, American Academy of Arts and Sciences, and the National Academy of Medicine of France. Sadelain has won the Breakthrough Prize for Life Sciences, Canada Gairdner International Award, Warren Alpert Foundation Prize, American Society of Gene and Cell Therapy Outstanding Achievement Award, Leopold Griffuel Award, INSERM International Prize, Jacob and Louise Gabbay Award in Biotechnology and Medicine, Passano Laureate, Pasteur Weizmann Servier Prize at the Academy of Sciences in Paris, Cancer Research Institute Coley award, and more.

Biography
Most recently, Adrian Bot, M. D., Ph. D. was the founding Chief Scientific Officer and Executive Vice President of Research and Development at Capstan Therapeutics, an Abbvie company developing next generation precision medicines with focus on in vivo CAR engineering. Previously, he held leadership roles at Kite Pharma and Kite, a Gilead Company, including Chief Scientific Officer and Vice President of Translational Medicine and Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Dr. Bot also served in various senior RD leadership positions at Mann Kind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M. D. in Romania in 1993, his Ph. D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California.

Biography
David Schaffer is the Hubbard Howe Professor at the University of California, Berkeley, and he also serves as the Director of QB3, Bakar Labs, and the Bakar Fellows Program. He completed his B. S. in chemical engineering at Stanford University in 1993, his Ph. D. in chemical engineering at MIT in 1998, and a postdoctoral fellowship at the Salk Institute for Biological Studies in 1999 before joining Berkeley in 1999. There, he applies engineering principles to optimize gene and stem cell therapies, work that includes developing the concept of applying directed evolution to engineer targeted and efficient viral gene therapy vectors as well as new technologies to investigate and control stem cell function. In addition, he has also co-founded seven companies from his lab that have advanced technologies into 10 human clinical trials. Finally, has received numerous recognitions including being elected to the National Academy of Engineering and National Academy of Inventors.

Biography
David Barrett joined Kite as the VP of Cell Biology in September 2022 where he serves as the lead of Translational Medicine and the Santa Monica and Philadelphia based research teams. He received a Masters in Biomedical Engineering, as well as a combined MD PhD from Virginia Commonwealth University in 2004. He went on to complete a Pediatrics Residency and Fellowship in Hematology Oncology at the Childrens Hospitalof Philadelphia in 2010 before starting his own lab as a physician scientist. During his time in the Cellular Therapyand Transplant Section at CHOP, he worked on the preclinical models for the cell therapy product that becameknown as Kymriah. Dr. Barrett cared for CAR T cell patients at CHOP from 2012-2020 and ran his lab investigatingtranslational science on CAR T trials, resulting in observations about cytokine release syndrome and the role ofmacrophages, the nature of antigen escape and the importance of juvenile cells in the pheresis and infusion products. In 2020 he left academics and joined Tmunity Therapeutics where he oversaw preclinical development andtranslational science on the solid tumor CAR T cell programs.

Biography
Arie S. Belldegrun is a trail‑blazing urologic‑oncologist‑turned‑biotech entrepreneur whose company‑building spree—from Agensys and Cougar to Kite Pharma—helped usher in the first FDA‑approved CAR‑T therapy and led to Kite’s $11.9 billion sale to Gilead Sciences. After that landmark exit, he co‑founded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of off‑the‑shelf (allogeneic) CAR‑T cell products toward the clinic. Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the real‑estate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact. Over three decades on UCLA’s faculty, he has authored 500‑plus scientific papers, mentored a generation of physician‑scientists, and kept patient benefit at the center of every deal—cementing his reputation as one of precision medicine’s most influential builders.

Biography
Arie S. Belldegrun is a trail‑blazing urologic‑oncologist‑turned‑biotech entrepreneur whose company‑building spree—from Agensys and Cougar to Kite Pharma—helped usher in the first FDA‑approved CAR‑T therapy and led to Kite’s $11.9 billion sale to Gilead Sciences. After that landmark exit, he co‑founded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of off‑the‑shelf (allogeneic) CAR‑T cell products toward the clinic. Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the real‑estate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact. Over three decades on UCLA’s faculty, he has authored 500‑plus scientific papers, mentored a generation of physician‑scientists, and kept patient benefit at the center of every deal—cementing his reputation as one of precision medicine’s most influential builders.

Biography
Dr. Roybal is the Director of the UCSF Parker Institute for Cancer Immunotherapy and a Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He was awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy in 2017, the NIH New Innovator Award in 2018, and the Cancer Research Institute STAR Award in 2022. The Roybal Lab harnesses the tools of Synthetic Biology and Immunology to control and customize immune cell therapeutics for cancer and autoimmunity. His work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist (acquired by Gilead). He was also instrumental in developing universal CAR T cell technology in collaboration with Xyphos Biosciences (acquired by Astellas). Recently, he co-founded cell therapy companies Arsenal Bio (now clinical stage), Dispatch Biotherapeutics, and Moonlight Bio focused on the treatment of solid tumors.

Biography
Ken Drazan, MD, is the Chairman, CEO, and Co-Founder of Arsenal Bio, apioneering company in the field of cell therapy and gene editing. Prior tohis role at Arsenal Bio, Dr. Drazan served as President and Chief Business Officer of GRAIL, a company focused on early cancer detection which wasacquired by Illumina. He also founded and was a Board Director at Verb Surgical, which was later acquired by Johnson Johnson. Additionally, Dr. Drazan co-founded Bertram Capital, a private equity firm managing $1.9billion in assets. He earned his medical degree from Yale University. Throughout his career, Dr. Drazan has been instrumental in advancingtechnologies that leverage AI and high-performance computing in precisionmedicine, significantly impacting the fields of gene editing and celltherapy.

Biography
Fabian is driven by a strong sense of purpose and is passionate aboutbuilding the future of cell therapy manufacturing. With 10+ years of experience as an innovator and a leader, Fabian has established a trackrecord of assembling top-performing teams to successfully drive novelbioprocessing technologies from ideation to commercial readiness. Prior toco-founding Cellares, Fabian served as Chief Innovation Officer at Synthego, where he co-invented the companys proprietary RNA synthesizertechnology and helped grow the company from five to more than 230employees. He earned a masters degree in aerospace engineering from the Technical University of Munich, and an honors degree in technologymanagement from the Center for Digital Technology and Management, Munich.

Biography
Aliya Omer leads the global strategy and execution of the hematology and cell therapy portfolio, across hematology and solid tumors at Astra Zeneca. Previously, Aliya served as Vice President, US Franchise Head, Breast Cancer at Astra Zeneca. Aliya has over 20 years of experience in the pharmaceutical, biotechnology and consumer healthcare industries, with a strong record of success leading across functions and all stages of the product lifecycle. Before joining Astra Zeneca, Aliya served as Vice President, Corporate Development Head of Global Portfolio and Program Strategy at Kite Pharma, a Gilead company, where she played a key leadership role in shaping the future direction of Kite and establishing it as a global leader in cell therapy. Previously, Aliya spent twelve years at Novartis Oncology where she led multiple commercial teams in the US and Latin America. Aliya started her career in research and development at Johnson and Johnson.

Biography
Gudrun specializes in developing advanced genomics platforms, drawing onher experience in NGS development and background in biophysics andbiochemistry. She has made significant contributions to the field, including the development of the Nova Seq platform at Illumina, and the Aviti platform at Element. In the startup space, she played a key role insecuring Series B funding for Encodia through her work in proteomics. Currently, as the founder of Alida Biosciences, Gudrun is focused oncreating novel RNA epitranscriptomic technologies designed to advancebeyond primary transcriptomic sequence analysis, to empower a new frontierof RNA biology and enhancement of multi-omic studies.

Biography
Dr. Getts is the CEO and co-founder of Myeloid Therapeutics. Prior to Myeloid, he was the VP of Research at TCR2 (NASDAQ, TCRR) and a member of the leadership team that successfully guided the company through a series B ($120M) financing and an IPO ($80M). Dr. Gettss primary duties were to lead the companys target discovery, preclinical, and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline, and a successfully filed IND. Before TCR2, Dr. Getts was the primary inventor, founder, and CSO of Cour Pharmaceuticals Development Companya nanotechnology platform company focused on autoimmunity and inflammation. As a member of the companys leadership team, he assisted in negotiating several pharmaceutical company collaborations and licenses, including Takeda, which ultimately licensed TIMP-GLIA for $420M. Dr. Getts has received numerous honors and awards, over 10 issued patents, and many more pending patent applications. He is widely published, including over 45 peer-reviewed publications with seminal publications in Nature Biotechnology, Science Translational Medicine, and Nature Communications. Dr. Getts completed his postdoctoral training at Northwestern University in Stephen D. Millers laboratory. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.

Biography
Snehit Prabhu oversees data science, including bioinformatics andbiostatistics, for cancer cell therapy at Stanford. His team has supportedover a dozen clinical trials and 2 multi-center consortia, managing datafrom 1,500+ cell therapy recipients, across both adult and pediatricsettings. Under his leadership, Stanford has built several first-in-class, novel data platforms and service lines to integrate and analyze patientdata in real-time from multiple organizations. .

Biography
Arie S. Belldegrun is a trailblazing urologiconcologistturnedbiotechentrepreneur whose companybuilding spreefrom Agensys and Cougar to Kite Pharmahelped usher in the first FD Aapproved CART therapy and led to Kites $11.9 billion sale to Gilead Sciences. After that landmark exit, he cofounded Allogene Therapeutics and stillserves as its Executive Chairman, steering the next wave of offtheshelf (allogeneic) CART cell products toward the clinic. Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the realestate venture Breakthrough Properties, nurturing a constellation of startups thattranslate science into patient impact. Over three decades on UCL As faculty, he has authored 500plus scientificpapers, mentored a generation of physicianscientists, and kept patientbenefit at the center of every dealcementing his reputation as one of precision medicines most influential builders.

Talk

AI and Data Sciences Showcase:
OncoNex

Biography
David Kirn, MD, is co-founder and has served as Chief Executive Officer since inception in 2013. Dr. Kirn is also Professor of Bioengineering and Molecular Cellular Biology (Adjunct) at UC Berkeley where he teaches biotechnology entrepreneurship, including in the Robinson Life Sciences Business Entrepreneurship Program. He is a board director and co-Founder of the UC Berkeley Life Sciences Entrepreneurship Center. Over his 30 year career, Dr. Kirn has co-founded and been CEO of four viral vector-based genetic medicines companies, three of which to date were either acquired or went public. Dr. Kirn also held senior clinical research and development positions at Onyx Pharmaceuticals (VP) and Celgene (SVP), and was a senior consultant and strategic advisor on viral vector-based genetic medicines to Novartis, Bayer, Pfizer, Biogen and others. Dr. Kirn received a BA in Physiology (Departmental Citation; Phi Beta Kappa) from UC Berkeley, an MD (Alpha Omega Alpha) from UC San Francisco Medical School and completed internal medicine residency training at Harvard Medical School, Brigham Womens Hospital (including term as Chief Medical Resident at affiliated WRVA hospital). He completed medical oncology and clinical research fellowships at UC San Francisco, and he completed a certificate of business excellence from the Haas Business School at UC Berkeley. He was awarded the Johnson Johnson Entrepreneur Innovator award from the JJ Innovation Center, was named to The Medicine Maker Power List, Advanced Medicine in 2022, and was a 2024 Pharma Voice 100 honoree in the Standout Leaders category.

Biography
Manuel Leonetti is Director of Systems Biology at the Biohub in San Francisco, where he leads interdisciplinary efforts to map, model, and ultimately control cellular organization and state across scales. His team integrates high-throughput genome engineering, live-cell imaging, proteomics, and A IML to systematically dissect the molecular mechanisms that govern cellular behavior. He is the founding lead of Open Cell, a proteome-scale atlas of endogenously tagged human proteins that defines the spatial and interaction architecture of the cell, and currently spearheads a new program focused on learning the molecular rules of cell-state transitions to enable predictive and programmatic cellular control. Leonetti received his Ph. D. from The Rockefeller University, where he trained with Roderick Mac Kinnon on the structural and functional mechanisms of ion channels, and subsequently completed postdoctoral training with Jonathan Weissman at UCSF, developing scalable CRISPR-based genome engineering approaches in human cells.

Biography
Stacie, a former pharma and biotech leader, recently joined NVIDIA to further enable AI adoption across Healthcare and Life Sciences. She also serves as the Vice Chair of the Alliance for Artificial Intelligence in Healthcare (A AIH). In her 13+ years at GSK, she led RD initiatives and co-founded the A TOM consortium. More recently, she held leadership roles at AI Drug Discovery startups Atomwise, where she was a VP of Partnerships, and Bio Symetrics, here she was the Chief Strategy Officer. Stacie holds a B. S. in Chemistry from UC Berkeley and a Ph. D. in Organic Chemistry from UC Irvine.

Biography
Fabian is driven by a strong sense of purpose and is passionate about building the future of cell therapy manufacturing. With 10+ years of experience as an innovator and a leader, Fabian has established a track record of assembling top-performing teams to successfully drive novel bioprocessing technologies from ideation to commercial readiness. Prior to co-founding Cellares, Fabian served as Chief Innovation Officer at Synthego, where he co-invented the companys proprietary RNA synthesizer technology and helped grow the company from five to more than 230 employees. He earned a masters degree in aerospace engineering from the Technical University of Munich, and an honors degree in technology management from the Center for Digital Technology and Management, Munich.

Biography
Lynn Seely, M. D., has served as Lyells President and Chief Executive Officer since December 2022 and has been a member of our board of directors since May 2021. Dr. Seely was also previously the lead independent director for Blueprint Medicines Corporation acquired by Sanofi and a director for TORL Bio Therapeutics. Dr. Seely was formerly President and Chief Executive Officer and a member of the board of directors of Myovant Sciences, Inc., a biopharmaceutical company that gained marketing approval and launched ORGOVYX for men with advanced prostate cancer and MYFEMBREE for women with uterine fibroids and endometriosis. Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc. In this role, Dr. Seely oversaw the development and marketing approval of the blockbuster medicine XTANDI for men with castration-resistant prostate cancer and held leadership roles in drug development collaborations with Pfizer Inc. and Astellas Pharma US, Inc. Prior to joining Medivation, Dr. Seely served as Vice President of Clinical Development at Corgentech Inc., at Cytyc Health Corporation, and at Pro Duct Health, Inc., a medical device company acquired by Cytyc Corporation. Dr. Seely began her industry career in clinical development at Chiron Corporation. In addition to serving on the Lyell Board, Dr. Seely serves on the Board of Managers for Life Science Cares Bay Area. Dr. Seely received a B. A. in journalism from the University of Oklahoma and an M. D. from the University of Oklahoma College of Medicine. She completed her residency and served as Chief Resident in internal medicine at Yale New Haven Hospital, and she completed her fellowship in endocrinology and metabolism at the University of California, San Diego, where she was on faculty before joining industry.

Biography
Zachary (Zach) Roberts, M. D., Ph. D., is the Executive Vice President, Research Development, and Chief Medical Officer of Allogene. Zach is a trained immunologist and board-certified oncologist with extensive experience in clinical oncology, including the development of cell therapies. Before joining Allogene, Zach was Chief Medical Officer of Instil Bio, where he led development of both clinical and pre-clinical programs. Prior to that, Dr. Roberts held various roles of increasing responsibility at Kite Pharma (acquired by Gilead in 2017), where he was instrumental in the development and execution of the ZUMA trials across multiple indications for YESCARTA, the first autologous CAR T therapy approved for non-Hodgkin lymphoma. Before joining Kite, Zach led several solid tumor studies at Amgen. He holds an M. D. and Ph. D. in immunology from the University of Maryland, Baltimore and completed clinical and post-graduate training at Massachusetts General Hospital and the Dana-Farber Cancer Institute.

Biography
Dr. Trevor Martin is the co-founder and CEO of Mammoth Biosciences, where we are harnessing the diversity of nature to power the next generation of curative CRISPR therapies for genetic diseases, as well as improving human health and wellbeing. Through our AI enabled discovery and development of novel CRISPR systems, including from co-founder and Nobel Prize winner Jennifer Doudna's lab, we are enabling the full potential of our platform to read and write the code of life. Trevor earned his BA from Princeton University and his Ph.D. from Stanford. His scientific work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is an EY Entrepreneur of the Year 2021. Mammoth has raised over $465M from leading investors in the US and internationally.